Physician profile
Sumit Gupta
NPI 1952311920
$5,321.04
in general payments reported to CMS, 2019-2025
26 companies · $1,806 in 2025
The $1,806 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $21.31 · 2021: $701 · 2022: $885 · 2023: $1,002 · 2024: $906 · 2025: $1,806.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,714.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,713.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $662.31 | 2021-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $595.14 | 2021-2025 | |
| Aurinia Pharma U.S., INC. | $474.88 | 2021-2025 | Lupkynis |
| Amgen INC. | $447.89 | 2021-2025 | Tavneos, Krystexxa, Parsabiv |
| Otsuka America Pharmaceutical, INC. | $389.25 | 2020-2025 | Jynarque, Voyxact |
| Horizon Therapeutics Plc | $357.48 | 2021-2023 | Krystexxa |
| Calliditas Therapeutics US INC. | $347.39 | 2022-2025 | Tarpeyo |
| Mallinckrodt Hospital Products INC. | $334.80 | 2021-2025 | Terlivaz, Acthar |
| Novartis Pharmaceuticals Corporation | $231.76 | 2024-2025 | |
| Opko Pharmaceuticals, LLC | $201.06 | 2021-2024 | Rayaldee |
| Travere Therapeutics, INC. | $189.52 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $164.17 | 2023-2025 | Jardiance |
| Novo Nordisk INC | $145.04 | 2021-2025 | Ozempic |
| Akebia Therapeutics INC | $141.85 | 2021-2025 | Auryxia, Vafseo |
| Vantive US Healthcare LLC | $115.87 | 2025 | Renal - Acute |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $98.31 | 2022-2025 | Ultomiris |
| Ardelyx, INC. | $87.38 | 2025 | Ibsrela |
| Apellis Pharmaceuticals, INC. | $65.92 | 2025 | Empaveli |
| Fresenius USA Marketing, INC. | $65.45 | 2021-2022 | |
| Vifor Pharma, INC. | $55.97 | 2021-2025 | Veltassa |
| Glaxosmithkline, LLC. | $45.18 | 2023-2025 | Benlysta |
| Daiichi Sankyo INC. | $23.92 | 2023 | Injectafer |
| Chiesi USA, INC. | $22.47 | 2023 | Elfabrio |
| Renalytix Ai, INC. | $20.37 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Ani Pharmaceuticals, INC. | $19.37 | 2025 | Purified Cortrophin Gel |
| Cormedix INC. | $18.29 | 2024 | Defencath |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sumit Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.